Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

BCL2L14 (BCL2-like 14 (apoptosis facilitator))

Written2013-08Mark R Pickard, Gwyn T Williams
Institute of Science, Technology in Medicine, Keele University, Keele, United Kingdom

(Note : for Links provided by Atlas : click)


HGNC (Hugo) BCL2L14
HGNC Alias symbBCLG
HGNC Previous nameBCL2-like 14 (apoptosis facilitator)
LocusID (NCBI) 79370
Atlas_Id 774
Location 12p13.2  [Link to chromosome band 12p13]
Location_base_pair Starts at 12070939 and ends at 12099693 bp from pter ( according to GRCh38/hg38-Dec_2013)  [Mapping BCL2L14.png]
Local_order Flanked by ETV6 and LOC100506248 (prothymosin alpha-like).
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
BCL2L14 (12p13.2)::ETV6 (12p13.2)ETV6 (12p13.2)::BCL2L14 (12p13.2)MSRB3 (12q14.3)::BCL2L14 (12p13.2)
Note BCL2L14 encodes members of the Bcl-2 family. Proteins in the family contain at least one Bcl-2 homology (BH) domain (of which there are four in total; termed BH1-4) and regulate cell life/death decisions at the level of the mitochondrion (intrinsic apoptotic pathway). Family members can be broadly divided into anti-apoptotic and pro-apoptotic regulators; the former class includes Bcl-2, Mcl-1 and Bcl-xL, which contain all four BH domains, whereas the latter class can be subdivided into: i. effector molecules, such as the multidomain (BH1-3) Bax and Bak molecules, and ii. upstream sentinel BH3-only proteins (e.g. Bim, Bid, Puma and Noxa). Bcl-2 family members undergo complex protein-protein interactions with each other. Crucially, it is the balance between pro- and anti-apoptotic Bcl-2 family members which determines if activation of the mitochondrial (intrinsic) apoptotic pathway occurs and, ultimately, whether the cell lives or dies.
Human BCL2L14 was first characterized in 2001 (Guo et al., 2001). Two full-length transcripts, encoding long and short protein isoforms (termed Bcl-GL and Bcl-GS), were isolated. Bcl-GS is a BH3-only protein, whereas Bcl-GL unusually contains only BH2 and BH3 domains (Guo et al., 2001); a similar Bcl-2 family member, termed Bfk, has subsequently been identified (Coultas et al., 2003). The two Bcl-G isoforms exhibit pro-apoptotic activity, but Bcl-GL is less potent than Bcl-GS, attributed to negative regulation by the BH2 domain (Guo et al., 2001). Differences are also apparent between Bcl-GS and Bcl-GL in their patterns of tissue expression (restricted to testes versus ubiquitous), subcellular distribution (cytosolic organelles versus diffuse) and interaction with other Bcl-2 family members (Bcl-GS only shows interaction) (Guo et al., 2001). Pig and mouse BCL2L14 encode only one BclG protein isoform (termed pBcl-G and mBcl-G, respectively), which contains BH2 and BH3 domains, similar to Bcl-GL (Giam et al., 2012a; Jiang et al., 2012). Phylogenetic analysis of Bcl-G protein sequences from 14 different species has revealed the presence of three different clades comprising human/apes, rodents and pigs/cattle, raising the possibility of species differences in Bcl-G action (Jiang et al., 2012).
The BCL2L14 promoter contains a cAMP responsive element, an interferon-γ-activated site (GAS) and an interferon regulatory factor element (IRF-E); interferon-α and γ co-operatively hyperactivate BCL2L14 expression in hepatoma cells (Zhang et al., 2006). A consensus site for certain proline- and acid rich basic region leucine zipper proteins is also present; binding of thyrotroph embryonic factor (TEF) or albumin D-site-binding protein (DBP) enhances promoter activity, whereas binding of nuclear factor, interleukin-3 regulated (NFIL3) is repressive (Benito et al., 2006). BCL2L14 has also been identified as a p53 target gene; the putative binding site is located within the first intron (Miled et al., 2005). BCL2L14 expression is regulated in a reciprocal manner by protein kinase C (PKC) isozyme signalling; its expression is repressed by PKCε but enhanced by PKCδ (Caino et al., 2011). Along with other apoptotic regulatory genes and the putative tumour suppressor gene, WISP3, BCL2L14 has been identified as a target for oncogenic miR-221 (Vandenboom et al., 2008).
Several different post-translational modifications, which impact upon protein function, have been reported for Bcl-G isoforms. Bcl-GL is a target for phosphorylation, catalysed by the candidate oncoprotein maternal embryonic leucine zipper kinase (MELK), which is overexpressed in breast cancer and a range of other solid tumors (Lin et al., 2007). The N-terminal region (amino acids 12 - 71) of Bcl-GL (conserved in Bcl-GS) is required for this interaction, and its phosphorylation inhibits apoptotic activity (Lin et al., 2007). Furthermore, in mouse cells, mBclG is a target for modification by a ubiquitin-like protein, termed FUBI, which in humans is encoded by the putative tumour suppressor gene FAU (Nakamura and Tanigawa, 2003; Nakamura and Yamaguchi, 2006). The N-terminal region of mBclG appears to be cleaved from the adduct. In mouse macrophages the FUBI/mBclG complex associates with ERKs and inhibits their activation by MEK1; recent work has further demonstrated that the adduct enhances lipopolysaccharide/interferon γ - induced apoptosis (Watanabe et al., 2013). Indeed, in human cells, ectopic expression of FAU promotes apoptosis, and both Fau and BclGL are thought to act in the same pathway, with the pro-apoptotic activity of Fau being mediated via BclGL (Pickard et al., 2009; Pickard et al., 2010; Pickard et al., 2011). Finally, interactions between Bcl-GS and JAB1 (c-Jun activation domain binding protein-1; aka the fifth subunit of the COP9 signalosome or CSN5) have also been reported (Liu et al., 2008). The N-terminal region (amino acids 1 - 67) of Bcl-GS is required for this interaction, and these two genes co-operatively induce apoptosis in HeLa cells; JAB1 inhibits Bcl-2/Bcl-XL binding by the BH3 domain of Bcl-GS and knock-down studies indicate that JAB1 is essential for Bcl-GS to induce apoptosis (Liu et al., 2008).
BCL2L14 lies within 12p12, which is frequently deleted in lymphoid/myeloid malignancies and solid tumours, suggestive of the presence of tumour suppressor gene(s) in this locus (Montpetit et al., 2002). In the case of pre-B acute lymphoblastic leukemia, ETV6 (rather than BCL2L14) is the target of deletions (Montpetit et al., 2004). In advanced prostate cancer however, the minimal deleted region is more distal to the telomere and extends into 12p13 (Kibel et al., 2004); expression mapping has demonstrated reduced BCL2L14 expression (Kibel et al., 2004). BCL2L14 expression is also dysregulated in breast cancer (Pickard et al., 2009), ovarian cancer (Heinzelmann-Schwarz et al., 2006) and in tongue squamous cell carcinoma (Zhang et al., 2013). Mutations in the BH3 domain are not however common occurences in cancer (Soung et al., 2006; Yoo et al., 2007).
BCL2L14 expression is markedly up-regulated in CD4+ T-cells from patients with the autoimmune disorder, systemic lupus erythematosus (SLE) and several lines of evidence implicate this dysregulation in pathogenesis (Luo et al., 2009). Dysregulated expression of BCL2L14 in mammalian cells has also been noted in response to infection with a variety of pathogens (Flori et al., 2008; Mehra et al., 2010; Balas et al., 2011; Singh et al., 2011; Taubert et al., 2010; Almeida et al., 2012; Wang et al., 2012), indicative of a role in innate immunity.


  Figure 1. Alternative splicing of BCL2L14 yields at least three transcript variants. Note that exons only are drawn to scale and that only those transcript variants for which reference sequences exist are shown. Transcript variants 1 and 4 differ only in their 5'-UTR sequence and produce an identical protein isoform (Bcl-GL), whereas the coding sequence of transcript variant 2 is shorter and gives rise to a protein isoform (Bcl-GS) with a distinct C-terminus.
Description The gene is located on chromosome 12 on the plus strand at 12202778 bp from pter to 12364018 from pter (size is 161241 bases). It was originally thought to comprise 6 exons (Guo et al., 2001) but 7 possible additional exons have subsequently been identified (Montpetit et al., 2002).
Transcription The gene encodes multiple transcripts; reference sequences exist for 3 transcript variants. These give rise to two different protein isoforms (Fig. 1). Transcript variants 1 and 4 differ only in their 5'-UTR and both encode the same protein, termed isoform 1 or Bcl-GL. Usage of a different splice acceptor site results in the production of transcript variant 2. This contains extra nucleotides within the coding sequence, resulting in a frameshift and consequently a truncated protein product with distinct C-terminal amino acids, termed isoform 2 or Bcl-GS. Transcript variant 2 may be a candidate for nonsense-mediated mRNA decay (NMD), but the RefSeq record (NM_030766.1) has been retained, since there is evidence for the expression of protein product. However, the RefSeq (NM_138724.1) for a further variant, originally termed variant 3, which encodes Bcl-G-Median (Bcl-GM) (Montpetit et al., 2002), has been permanently suppressed, as this transcript is also a candidate for NMD and evidence for protein expression is lacking.
Pseudogene There are no known pseudogenes.


  Figure 2. Protein isoforms encoded by BCL2L14. Homologous sequence between the two isoforms is depicted by the same colour pattern. Note that BclGL contains BH2 and BH3 domains whereas BclGS is a BH3-only protein. Potential sites of post-translational modification/interaction with non-Bcl-2 family members are also indicated.
Description The two protein isoforms are members of the Bcl-2 family. Bcl-GL comprises 327 amino acids and contains BH2 and BH3 domains, whereas Bcl-GS comprises 252 amino acids and contains the BH3 domain only (Fig. 2). The two proteins are identical in sequence for the first 226 amino acids.
Expression Highest levels of gene expression in the adult human are found in testis, hence the name Bcl-G, for Bcl-Gonad. Indeed Bcl-GS is uniquely expressed in this tissue (as also noted for Bcl-GM) (Guo et al., 2001; Montpetit et al., 2002). Bcl-GL is predominantly expressed in testis, with transcripts also present in lung, pancreas, prostate, bone marrow and colon (Guo et al., 2001; Montpetit et al., 2002). The expression of Bcl-GL has also been reported in freshly isolated human T-lymphocytes (CD4+ and CD8+ cells) and B-lymphocytes (Luo et al., 2009). Both Bcl-GL and Bcl-GS transcripts are expressed in a wide range of breast cancer cell lines and cultured mammary epithelial cells, but protein expression has been demonstrated for the former isoform only (Benito et al., 2006; Lin et al., 2007). Bcl-G transcript expression is more variable across prostate cell lines (Pickard et al., 2010). High levels of Bcl-GS transcripts are found in testicular embryonal cancer cell lines, with lower levels present in urinary bladder and mantle cell lymphoma cell lines, followed by myeloid and breast cancer cell lines, but protein was detected for the testicular embryonal cancer cell lines only (Benito et al., 2006).
Localisation Expression of GFP-tagged proteins in COS-7 cells has revealed a diffuse localization throughout the cell for Bcl-GL (similar to GFP alone), but a more punctate cytosolic localization, with partial co-localization to mitochondria, for Bcl-GS (Guo et al., 2001). The latter has been confirmed using Myc-tagged Bcl-GS (Liu et al., 2008). Deletion of the BH3 domain from Bcl-GS has no effect on its subcellular distribution, despite preventing interaction with Bcl-XL (Guo et al., 2001). However interaction with JAB1 results in a more diffuse cytoplasmic localisation for Bcl-GS (Liu et al., 2008).
Function The original paper on BCL2L14 reported that GFP- or FLAG-tagged Bcl-GL and Bcl-GS have pro-apoptotic activity in a range of cell lines (COS-7, HEK293T and PC3), and that the latter is the more potent isoform (Guo et al., 2001). Deletion of the BH2 domain from Bcl-GL allowed its interaction with Bcl-XL and enhanced apoptotic activity, whereas the BH3 domain of Bcl-GS was required for interaction with Bcl-XL and apoptotic activity (Guo et al., 2001).
The pro-apoptotic activity of Bcl-GL in COS-7 cells has been independently confirmed, and it has been further demonstrated that this activity is negatively regulated by phosphorylation, catalyzed by MELK (Lin et al., 2007). Similarly, Bcl-GS has been reported to induce basal apoptosis in HeLa cells; an effect that is potentiated by JAB1 (Liu et al., 2008). The latter is thought to out-compete Bcl-2/Bcl-XL for binding of Bcl-GS (Liu et al., 2008). On the other hand, transfection of Huh-7 cells with Bcl-GL has no effect on basal apoptosis (Zhang et al., 2006), while the survival of HCT116 and NTERA2 cells is unaffected by elevated levels of Bcl-GS consequent upon ectopic TEF expression (Benito et al., 2006), suggesting that cell context is important for the apoptotic activity of Bcl-G protein isoforms. Crucially lentiviral transfection of Bcl-GL results in enhanced apoptosis of CD4+ T-cells from healthy subjects, demonstrating that pro-apoptotic activity is not restricted to transformed cells (Luo et al., 2009).
Furthermore, siRNA-mediated silencing of BCL2L14 gene expression attenuates apoptosis induction in several cell lines in response to diverse stimuli, including: ultraviolet-C irradiation (22Rv1 and HEK293T cells) (Pickard et al., 2010; Pickard et al., 2011), etoposide (HCT116 cells) (Benito et al., 2006), neratinib (SKBR-3 cells) (Seyhan et al., 2012), p53-induction (Saos-2 cells) (Miled et al., 2005), and ectopic expression of the putative tumour suppressor gene FAU (HEK293T cells) (Pickard et al., 2011). BCL2L14 is itself a target gene for the apoptosis master regulator p53 (Miled et al., 2005), and it is one of a subset of pro-apoptotic genes whose expression is hyperactivated in response to interferon-α and -γ co-treatment of hepatoma cells (Zhang et al., 2006). Its expression is also increased in mammalian cells following exposure to a diverse range of apoptotic stimuli (including chemotherapeutic agents) such as: gamma- radiation therapy (Finnberg et al., 2008), UV-C irradiation (Pickard et al., 2011), arsenic trioxide (Galimberti et al., 2012), nanoparticulate tetraiodothyroacetic acid (Glinskii et al., 2009), etoposide and cisplatin (Benito et al., 2006).
Mutations in pancreatic/duodenum homeobox protein 1 (PDX1) can result in human type 2 diabetes. Haploinsufficiency of this gene in mice also causes diabetes and is associated with enhanced apoptosis/necrosis of β-cells. In this regard, BCL2L14 has been identified as one of several genes encoding pro-apoptotic Bcl-2 family members whose expression is markedly up-regulated following shRNA-mediated depletion of Pdx1 in mouse insulinoma MIN6 cells (Fujimoto et al., 2010). Additionally BCL2L14 is one of several pro-apoptotic genes that is up-regulated upon exposure of human fibroblasts to pressure-induced oxidative stress (Oh et al., 2008).
The recent production of a mouse in which BCL2L14 is inactivated has demonstrated no apparent deleterious effects on cell types that normally express this gene (Giam et al., 2012b), perhaps suggesting some degree of functional redundancy. These authors further demonstrated that mBclG had negligible pro-apoptotic activity in human 293T cells and that the BH3 domain was incapable of binding Bcl-2 family members. Rather mBclG was capable of binding several novel partners, including transport particle protein (TRAPP) complex proteins, suggesting a potential role for mBclG in vesicle trafficking (Giam et al., 2012b). As regards pig Bcl-G, its ectopic expression in a porcine kidney cell line stimulates apoptosis induced by polyinosinic: polycytidylic acid (synthetic analogue of dsRNA and mimic of viral infection) (Jiang et al., 2012).
Homology Homologues of BCL2L14 have been identified in a wide range of species (e.g. see Jiang et al., 2012). However, the Bcl-GS protein isoform is specific to humans (Giam et al., 2012a). Mouse and pig Bcl-G share 68% and 71% amino acid identity, respectively, with human Bcl-GL.

Implicated in

Entity Prostate cancer
Note In advanced prostate cancer, deletion of 12p12 is frequently seen. Expression mapping of genes within/adjacent to the minimal deleted region in clinical tumours has demonstrated reduced expression of BCL2L14 and two other genes (DUSP16 and FLJ10298) (Kibel et al., 2004); reduced expression of BCL2L14 has been independently confirmed (Pickard et al., 2010). In the latter study, transcript levels were highly correlated with those of FAU, which also regulates apoptosis and which may act via the post-translational modification of Bcl-G (Pickard et al., 2010). Notably, down-regulation of BCL2L14 gene expression in the prostate cancer 22Rv1 cell line protects cells from apoptosis induction by ultraviolet-C irradiation (Pickard et al., 2010). BCL2L14 has been identified as a member of a four gene signature that accurately predicts prostate cancer recurrence, but high expression of BCL2L14 is associated with tumour recurrence (Latil et al., 2003).
Entity Breast cancer
Note Single nucleotide polymorphisms of high frequency loss of heterozygosity that affect BCL2L14 are found more commonly in infiltrating ductal carcinoma than in infiltrating lobular carcinoma of the breast (Loo et al., 2008). In breast ductal carcinoma, BCL2L14 expression is reduced, and silencing of BCL2L14 expression in the T-47D breast cancer cell line attenuates apoptosis induction by exogenous stimuli (Pickard et al., 2009). A genome-wide RNAi screen has recently shown that BCL2L14 silencing in SKBR-3 results in resistance to the novel pan-ErbB inhibitor, neratinib (Seyhan et al., 2012). BCL2L14 has also been implicated in the anti-survival effects of nanoparticulate tetraiodothyroacetic acid on MDA-MB-231 cells (Glinskii et al., 2009).
As regards genes involved in the post-translational modification of Bcl-G, FAU expression is down-regulated and MELK expression is up-regulated in breast tumour tissue (Pickard et al., 2009). These latter changes were associated with poor patient prognosis, but no relationship was apparent between BCL2L14 gene expression and patient survival (Pickard et al., 2009), suggesting that the regulation of Bcl-G activity by post-translational modification is more important than the level of BCL2L14 expression per se in determining patient survival.
Entity Ovarian cancer
Note Elevated levels of BCL2L14 gene expression have been reported for mucinous ovarian cancer relative to other histological subtypes of ovarian cancer (Heinzelmann-Schwarz et al., 2006). The functional significance of these changes are unknown. Subdivision of patients with high grade ovarian serous carcinoma into TP53 mutation-positive and p53 protein-null groups has revealed a number of differences in the genomic landscape, including gains of 12p13.2-12p13.1 (affecting DUSP16, BCL2L14 and ETV6) in the former group (Wojnarowicz et al., 2012). TP53 mutation-positive patients were also characterized by increased overall and disease-free survival (Wojnarowicz et al., 2012).
Entity Cervical cancer
Note An integration site for HPV16 in cervical carcinoma has been mapped to BCL2L14 (Xu et al., 2013).
Entity Lung cancer
Note Analysis of variants in inflammation pathway genes has identified single nucleotide polymorphisms of BCL2L14 in former smokers that are associated with increased risk of developing lung cancer (Spitz et al., 2012).
Entity Precursor B acute lymphoblastic leukemia (ALL)
Note A novel TEL-AML1 fusion transcript, comprising an in-frame insertion of 33 nucleotides derived from BCL2L14 between exon 5 of TEL and exon 2 of AML1 has been described in a case of pediatric precursor B ALL (Abdelhaleem et al., 2006). This fusion transcript appears to be rare, and its biological effects are unknown.
Entity Tongue squamous cell carcinoma
Note BCL2L14 expression has been reported to be markedly up-regulated in tongue squamous cell carcinoma tissue (Zhang et al., 2013).
Entity Systemic lupus erythematosus (SLE)
Note BCL2L14 expression is up-regulated (ca. 8-fold) in CD4+ T-cells (but not CD8+ or B-cells) from patients with systemic lupus erythematosus (SLE) (Luo et al., 2009). In SLE, apoptosis is increased in CD4+ T-cells, and the degree of apoptosis in freshly isolated cells from SLE patients was directly correlated with Bcl-GL levels, as were other measures of disease activity status (Luo et al., 2009). Healthy control CD4+ T-cells in vitro demonstrated enhanced apoptosis both after transfection with a lentiviral vector expressing BclGL and after treatment with serum from SLE patients; the latter effect was associated with increased BclGL cellular levels and could be partially inhibited by prior knockdown of BclGL (Luo et al., 2009). The serum factor(s) that mediate this response remain unknown; whilst interferon-α was increased in SLE sera it alone could not account for enhanced Bcl-GL cellular levels (Luo et al., 2009).
Entity Innate immune response
Note There are several reports of dysregulated expression of BCL2L14 in response to infection with a wide range of pathogens/parasites. For example, in Rhesus Macaque monkeys infected with Mycobacterium tuberculosis, BCL2L14 expression is initially enhanced in granulomas relative to normal lung tissue during the acute phase of disease but silenced several weeks post-infection (Mehra et al., 2010). While multiple markers of the pro-inflammatory response show a similar pattern, the silencing of BCL2L14 in chronic disease may contribute to pathogen survival. Studies with murine cells have further shown that exosomes derived from macrophages infected with Mycobacterium tuberculosis can block the activation of a subset of interferon-γ inducible genes, including BCL2L14, which may serve to suppress the host innate immune response beyond the site of infection (Singh et al., 2011). BCL2L14 is one of several Bcl-2 family members that is dysregulated in bovine endothelial cells following infection with the parasite Eimeria bovis (Taubert et al., 2010). It is markedly upregulated in human alveolar macrophages within a few hours of infection with H1N1 influenza A virus PR/8 (Wang et al., 2012) and it is also induced following the infection of human monocyte-derived dendritic cells with wild type Dengue 3 virus (a Flavivirus) or the chimeric CYD3 vaccine virus (Balas et al., 2011). On the other hand, BCL2L14 expression is down-regulated in porcine epithelial cells following infection with Pseudorabies virus (a herpes virus) (Flori et al., 2008).
BCL2L14 may also be implicated in the host response to viral evasion mechanisms per se. For example, selective expression of the African Swine Fever Virus evasion gene, A238L, in mouse T-lymphocytes results in the production of an aggressive lymphoma (Almeida et al., 2012). Transgenic animals exhibit massively enlarged thymuses characterized, inter alia, by enhanced BCL2L14 expression and apoptosis (Almeida et al., 2012).
While attendant changes in host cell interferon signalling may account for many of the above changes in BCL2L14 expression, it should be noted that Bcl-G can directly interact with a component of the Flavivirus replication complex (Le Breton et al., 2011). However, the biological significance of this interaction for both host and virus remains to be determined. The 3'-UTR of BCL2L14 transcripts also contains potential binding sites for Epstein-Barr virus-derived miRNAs (Marquitz et al., 2011).


A novel TEL-AML1 fusion transcript involving the pro-apoptotic gene BCL-G in pediatric precursor B acute lymphoblastic leukemia.
Abdelhaleem M, Yi Q, Beimnet K, Hitzler J.
Leukemia. 2006 Jul;20(7):1294. Epub 2006 May 4.
PMID 16673018
Neoplastic transformation of T lymphocytes through transgenic expression of a virus host modification protein.
Almeida SC, de Oliveira VL, Ventura S, Bofill M, Parkhouse RM.
PLoS One. 2012;7(4):e34140. doi: 10.1371/journal.pone.0034140. Epub 2012 Apr 27.
PMID 22558084
Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strains.
Balas C, Kennel A, Deauvieau F, Sodoyer R, Arnaud-Barbe N, Lang J, Guy B.
J Infect Dis. 2011 Jan 1;203(1):103-8. doi: 10.1093/infdis/jiq022. (REVIEW)
PMID 21148502
A novel role for proline- and acid-rich basic region leucine zipper (PAR bZIP) proteins in the transcriptional regulation of a BH3-only proapoptotic gene.
Benito A, Gutierrez O, Pipaon C, Real PJ, Gachon F, Ritchie AE, Fernandez-Luna JL.
J Biol Chem. 2006 Dec 15;281(50):38351-7. Epub 2006 Oct 20.
PMID 17057225
Differential regulation of gene expression by protein kinase C isozymes as determined by genome-wide expression analysis.
Caino MC, von Burstin VA, Lopez-Haber C, Kazanietz MG.
J Biol Chem. 2011 Apr 1;286(13):11254-64. doi: 10.1074/jbc.M110.194332. Epub 2011 Jan 20.
PMID 21252239
Bfk: a novel weakly proapoptotic member of the Bcl-2 protein family with a BH3 and a BH2 region.
Coultas L, Pellegrini M, Visvader JE, Lindeman GJ, Chen L, Adams JM, Huang DC, Strasser A.
Cell Death Differ. 2003 Feb;10(2):185-92.
PMID 12700646
Gamma-radiation (GR) triggers a unique gene expression profile associated with cell death compared to proton radiation (PR) in mice in vivo.
Finnberg N, Wambi C, Ware JH, Kennedy AR, El-Deiry WS.
Cancer Biol Ther. 2008 Dec;7(12):2023-33. Epub 2008 Dec 17.
PMID 19106632
Transcriptomic analysis of the dialogue between Pseudorabies virus and porcine epithelial cells during infection.
Flori L, Rogel-Gaillard C, Cochet M, Lemonnier G, Hugot K, Chardon P, Robin S, Lefevre F.
BMC Genomics. 2008 Mar 10;9:123. doi: 10.1186/1471-2164-9-123.
PMID 18331636
Loss of Nix in Pdx1-deficient mice prevents apoptotic and necrotic β cell death and diabetes.
Fujimoto K, Ford EL, Tran H, Wice BM, Crosby SD, Dorn GW 2nd, Polonsky KS.
J Clin Invest. 2010 Nov;120(11):4031-9. doi: 10.1172/JCI44011. Epub 2010 Oct 11.
PMID 20978346
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study.
Galimberti S, Guerrini F, Salvi F, Petrini I, Gioia D, Messa E, Palumbo GA, Cilloni D, Petrini M, Levis A.
J Hematol Oncol. 2012 Sep 10;5:53. doi: 10.1186/1756-8722-5-53.
PMID 22964015
Detection of Bcl-2 family member Bcl-G in mouse tissues using new monoclonal antibodies.
Giam M, Mintern JD, Rautureau GJ, Hinds MG, Strasser A, Bouillet P.
Cell Death Dis. 2012a Aug 23;3:e378. doi: 10.1038/cddis.2012.117.
PMID 22914326
Bcl-2 family member Bcl-G is not a proapoptotic protein.
Giam M, Okamoto T, Mintern JD, Strasser A, Bouillet P.
Cell Death Dis. 2012b Oct 11;3:e404. doi: 10.1038/cddis.2012.130.
PMID 23059823
Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac).
Glinskii AB, Glinsky GV, Lin HY, Tang HY, Sun M, Davis FB, Luidens MK, Mousa SA, Hercbergs AH, Davis PJ.
Cell Cycle. 2009 Nov 1;8(21):3554-62. Epub 2009 Nov 1.
PMID 19838061
Bcl-G, a novel pro-apoptotic member of the Bcl-2 family.
Guo B, Godzik A, Reed JC.
J Biol Chem. 2001 Jan 26;276(4):2780-5. Epub 2000 Oct 27.
PMID 11054413
A distinct molecular profile associated with mucinous epithelial ovarian cancer.
Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry JP, Scolyer RA, Smith AN, Bali A, Vanden Bergh P, Baron-Hay S, Scott C, Fink D, Hacker NF, Sutherland RL, O'Brien PM.
Br J Cancer. 2006 Mar 27;94(6):904-13.
PMID 16508639
BCL-G as a new candidate gene for immune responses in pigs: bioinformatic analysis and functional characterization.
Jiang P, Li D, Bi L, Zhang D.
Vet Immunol Immunopathol. 2012 Nov 15;150(1-2):112-7. doi: 10.1016/j.vetimm.2012.08.001. Epub 2012 Aug 9.
PMID 22980516
Expression mapping at 12p12-13 in advanced prostate carcinoma.
Kibel AS, Huagen J, Guo C, Isaacs WB, Yan Y, Pienta KJ, Goodfellow PJ.
Int J Cancer. 2004 May 1;109(5):668-72.
PMID 14999772
Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior.
Latil A, Bieche I, Chene L, Laurendeau I, Berthon P, Cussenot O, Vidaud M.
Clin Cancer Res. 2003 Nov 15;9(15):5477-85.
PMID 14654526
Flavivirus NS3 and NS5 proteins interaction network: a high-throughput yeast two-hybrid screen.
Le Breton M, Meyniel-Schicklin L, Deloire A, Coutard B, Canard B, de Lamballerie X, Andre P, Rabourdin-Combe C, Lotteau V, Davoust N.
BMC Microbiol. 2011 Oct 20;11:234. doi: 10.1186/1471-2180-11-234.
PMID 22014111
Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family.
Lin ML, Park JH, Nishidate T, Nakamura Y, Katagiri T.
Breast Cancer Res. 2007;9(1):R17.
PMID 17280616
JAB1 accelerates mitochondrial apoptosis by interaction with proapoptotic BclGs.
Liu X, Pan Z, Zhang L, Sun Q, Wan J, Tian C, Xing G, Yang J, Liu X, Jiang J, He F.
Cell Signal. 2008 Jan;20(1):230-40. Epub 2007 Oct 16.
PMID 18006276
Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer.
Loo LW, Ton C, Wang YW, Grove DI, Bouzek H, Vartanian N, Lin MG, Yuan X, Lawton TL, Daling JR, Malone KE, Li CI, Hsu L, Porter PL.
Genes Chromosomes Cancer. 2008 Dec;47(12):1049-66. doi: 10.1002/gcc.20610.
PMID 18720524
Upregulated BclG(L) expression enhances apoptosis of peripheral blood CD4+ T lymphocytes in patients with systemic lupus erythematosus.
Luo N, Wu Y, Chen Y, Yang Z, Guo S, Fei L, Zhou D, Yang C, Wu S, Ni B, Hao F, Wu Y.
Clin Immunol. 2009 Sep;132(3):349-61. doi: 10.1016/j.clim.2009.05.010. Epub 2009 Jun 12.
PMID 19524489
The Epstein-Barr Virus BART microRNAs target the pro-apoptotic protein Bim.
Marquitz AR, Mathur A, Nam CS, Raab-Traub N.
Virology. 2011 Apr 10;412(2):392-400. doi: 10.1016/j.virol.2011.01.028. Epub 2011 Feb 18.
PMID 21333317
Transcriptional reprogramming in nonhuman primate (rhesus macaque) tuberculosis granulomas.
Mehra S, Pahar B, Dutta NK, Conerly CN, Philippi-Falkenstein K, Alvarez X, Kaushal D.
PLoS One. 2010 Aug 31;5(8):e12266. doi: 10.1371/journal.pone.0012266.
PMID 20824205
A genomic map of p53 binding sites identifies novel p53 targets involved in an apoptotic network.
Miled C, Pontoglio M, Garbay S, Yaniv M, Weitzman JB.
Cancer Res. 2005 Jun 15;65(12):5096-104.
PMID 15958553
Mutational and expression analysis of the chromosome 12p candidate tumor suppressor genes in pre-B acute lymphoblastic leukemia.
Montpetit A, Larose J, Boily G, Langlois S, Trudel N, Sinnett D.
Leukemia. 2004 Sep;18(9):1499-504.
PMID 15284860
The ubiquitin-like protein MNSFbeta regulates ERK-MAPK cascade.
Nakamura M, Yamaguchi S.
J Biol Chem. 2006 Jun 23;281(25):16861-9. Epub 2006 Apr 18.
PMID 16621790
Comparison of the effects of 40% oxygen and two atmospheric absolute air pressure conditions on stress-induced premature senescence of normal human diploid fibroblasts.
Oh S, Lee E, Lee J, Lim Y, Kim J, Woo S.
Cell Stress Chaperones. 2008 Dec;13(4):447-58. doi: 10.1007/s12192-008-0041-5. Epub 2008 May 9.
PMID 18465208
Candidate tumour suppressor Fau regulates apoptosis in human cells: an essential role for Bcl-G.
Pickard MR, Mourtada-Maarabouni M, Williams GT.
Biochim Biophys Acta. 2011 Sep;1812(9):1146-53. doi: 10.1016/j.bbadis.2011.04.009. Epub 2011 Apr 29.
PMID 21550398
A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers.
Seyhan AA, Varadarajan U, Choe S, Liu W, Ryan TE.
Mol Biosyst. 2012 Apr;8(5):1553-70. doi: 10.1039/c2mb05512k. Epub 2012 Mar 23.
PMID 22446932
Exosomes released from M. tuberculosis infected cells can suppress IFN-γ mediated activation of naive macrophages.
Singh PP, LeMaire C, Tan JC, Zeng E, Schorey JS.
PLoS One. 2011 Apr 14;6(4):e18564. doi: 10.1371/journal.pone.0018564.
PMID 21533172
BH3 domain mutation of proapoptotic genes Bad, Bmf and Bcl-G is rare in transitional cell carcinomas of the urinary bladder.
Soung YH, Lee JW, Park WS, Nam SW, Lee JY, Yoo NJ, Lee SH.
Pathology. 2006 Feb;38(1):33-4.
PMID 16484005
Multistage analysis of variants in the inflammation pathway and lung cancer risk in smokers.
Spitz MR, Gorlov IP, Dong Q, Wu X, Chen W, Chang DW, Etzel CJ, Caporaso NE, Zhao Y, Christiani DC, Brennan P, Albanes D, Shi J, Thun M, Landi MT, Amos CI.
Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1213-21. doi: 10.1158/1055-9965.EPI-12-0352-T. Epub 2012 May 9.
PMID 22573796
Microarray-based transcriptional profiling of Eimeria bovis-infected bovine endothelial host cells.
Taubert A, Wimmers K, Ponsuksili S, Jimenez CA, Zahner H, Hermosilla C.
Vet Res. 2010 Sep-Oct;41(5):70. doi: 10.1051/vetres/2010041. Epub 2010 Jul 12.
PMID 20615380
MicroRNA and Cancer: Tiny Molecules with Major Implications.
Vandenboom Ii TG, Li Y, Philip PA, Sarkar FH.
Curr Genomics. 2008 Apr;9(2):97-109. doi: 10.2174/138920208784139555.
PMID 19440450
Innate immune response of human alveolar macrophages during influenza A infection.
Wang J, Nikrad MP, Travanty EA, Zhou B, Phang T, Gao B, Alford T, Ito Y, Nahreini P, Hartshorn K, Wentworth D, Dinarello CA, Mason RJ.
PLoS One. 2012;7(3):e29879. doi: 10.1371/journal.pone.0029879. Epub 2012 Mar 2.
PMID 22396727
Ubiquitin-like protein MNSFβ covalently binds to Bcl-G and enhances lipopolysaccharide/interferon γ-induced apoptosis in macrophages.
Watanabe J, Nakagawa M, Watanabe N, Nakamura M.
FEBS J. 2013 Mar;280(5):1281-93. doi: 10.1111/febs.12120. Epub 2013 Feb 11.
PMID 23298187
The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.
Wojnarowicz PM, Oros KK, Quinn MC, Arcand SL, Gambaro K, Madore J, Birch AH, de Ladurantaye M, Rahimi K, Provencher DM, Mes-Masson AM, Greenwood CM, Tonin PN.
PLoS One. 2012;7(9):e45484. doi: 10.1371/journal.pone.0045484. Epub 2012 Sep 20.
PMID 23029043
Multiplex Identification of Human Papillomavirus 16 DNA Integration Sites in Cervical Carcinomas.
Xu B, Chotewutmontri S, Wolf S, Klos U, Schmitz M, Durst M, Schwarz E.
PLoS One. 2013 Jun 18;8(6):e66693. Print 2013.
PMID 23824673
Mutational analysis of the BH3 domains of proapoptotic Bcl-2 family genes Bad, Bmf and Bcl-G in laryngeal squamous cell carcinomas.
Yoo NJ, Soung YH, Lee SH, Jeong EG, Lee SH.
Tumori. 2007 Mar-Apr;93(2):195-7.
PMID 17557568
Genome-wide analysis of DNA methylation in tongue squamous cell carcinoma.
Zhang S, Feng XL, Shi L, Gong CJ, He ZJ, Wu HJ, Ling TY.
Oncol Rep. 2013 May;29(5):1819-26. doi: 10.3892/or.2013.2309. Epub 2013 Feb 27.
PMID 23446731
Hyper-activated IRF-1 and STAT1 contribute to enhanced interferon stimulated gene (ISG) expression by interferon alpha and gamma co-treatment in human hepatoma cells.
Zhang XN, Liu JX, Hu YW, Chen H, Yuan ZH.
Biochim Biophys Acta. 2006 Aug-Sep;1759(8-9):417-25.
PMID 16987558


This paper should be referenced as such :
Pickard, MR ; Williams, GT
BCL2L14 (BCL2-like 14 (apoptosis facilitator))
Atlas Genet Cytogenet Oncol Haematol. 2014;18(3):152-159.
Free journal version : [ pdf ]   [ DOI ]

Other Leukemias implicated (Data extracted from papers in the Atlas) [ 1 ]
  t(12;12)(p13;p13) ETV6::BCL2L14

External links


HGNC (Hugo)BCL2L14   16657
Atlas Explorer : (Salamanque)BCL2L14
Entrez_Gene (NCBI)BCL2L14    BCL2 like 14
GeneCards (Weizmann)BCL2L14
Ensembl hg19 (Hinxton)ENSG00000121380 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000121380 [Gene_View]  ENSG00000121380 [Sequence]  chr12:12070939-12099693 [Contig_View]  BCL2L14 [Vega]
ICGC DataPortalENSG00000121380
TCGA cBioPortalBCL2L14
AceView (NCBI)BCL2L14
Genatlas (Paris)BCL2L14
SOURCE (Princeton)BCL2L14
Genetics Home Reference (NIH)BCL2L14
Genomic and cartography
GoldenPath hg38 (UCSC)BCL2L14  -     chr12:12070939-12099693 +  12p13.2   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)BCL2L14  -     12p13.2   [Description]    (hg19-Feb_2009)
GoldenPathBCL2L14 - 12p13.2 [CytoView hg19]  BCL2L14 - 12p13.2 [CytoView hg38]
Genome Data Viewer NCBIBCL2L14 [Mapview hg19]  
Gene and transcription
Genbank (Entrez)AF281254 AF281255 AK000127 AK026440 AK223415
RefSeq transcript (Entrez)NM_001370268 NM_001370269 NM_030766 NM_138722 NM_138723 NM_138724
Consensus coding sequences : CCDS (NCBI)BCL2L14
Gene ExpressionBCL2L14 [ NCBI-GEO ]   BCL2L14 [ EBI - ARRAY_EXPRESS ]   BCL2L14 [ SEEK ]   BCL2L14 [ MEM ]
Gene Expression Viewer (FireBrowse)BCL2L14 [ Firebrowse - Broad ]
GenevisibleExpression of BCL2L14 in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)79370
GTEX Portal (Tissue expression)BCL2L14
Human Protein AtlasENSG00000121380-BCL2L14 [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ9BZR8   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtQ9BZR8  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProQ9BZR8
Domaine pattern : Prosite (Expaxy)BCL2_FAMILY (PS50062)   
Domains : Interpro (EBI)Bcl2-like    BCL2L14    Blc2-like_sf   
Domain families : Pfam (Sanger)
Domain families : Pfam (NCBI)
Conserved Domain (NCBI)BCL2L14
AlphaFold pdb e-kbQ9BZR8   
Human Protein Atlas [tissue]ENSG00000121380-BCL2L14 [tissue]
Protein Interaction databases
IntAct (EBI)Q9BZR8
Ontologies - Pathways
Ontology : AmiGOprotein binding  cytosol  cytosol  apoptotic process  endomembrane system  membrane  protein kinase binding  intracellular organelle  regulation of extrinsic apoptotic signaling pathway  
Ontology : EGO-EBIprotein binding  cytosol  cytosol  apoptotic process  endomembrane system  membrane  protein kinase binding  intracellular organelle  regulation of extrinsic apoptotic signaling pathway  
REACTOMEQ9BZR8 [protein]
REACTOME PathwaysR-HSA-6803205 [pathway]   
NDEx NetworkBCL2L14
Atlas of Cancer Signalling NetworkBCL2L14
Wikipedia pathwaysBCL2L14
Orthology - Evolution
GeneTree (enSembl)ENSG00000121380
Phylogenetic Trees/Animal Genes : TreeFamBCL2L14
Homologs : HomoloGeneBCL2L14
Homology/Alignments : Family Browser (UCSC)BCL2L14
Gene fusions - Rearrangements
Fusion : MitelmanBCL2L14::ETV6 [12p13.2/12p13.2]  
Fusion : MitelmanMSRB3::BCL2L14 [12q14.3/12p13.2]  
Fusion : FusionHubBCL2L14--ETV6    BCL2L14--GPR19    BCL2L14--SHARPIN    MSRB3--BCL2L14   
Fusion : QuiverBCL2L14
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerBCL2L14 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)BCL2L14
Exome Variant ServerBCL2L14
GNOMAD BrowserENSG00000121380
Varsome BrowserBCL2L14
ACMGBCL2L14 variants
Genomic Variants (DGV)BCL2L14 [DGVbeta]
DECIPHERBCL2L14 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisBCL2L14 
ICGC Data PortalBCL2L14 
TCGA Data PortalBCL2L14 
Broad Tumor PortalBCL2L14
OASIS PortalBCL2L14 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICBCL2L14  [overview]  [genome browser]  [tissue]  [distribution]  
Somatic Mutations in Cancer : COSMIC3DBCL2L14
Mutations and Diseases : HGMDBCL2L14
LOVD (Leiden Open Variation Database)[gene] [transcripts] [variants]
DgiDB (Drug Gene Interaction Database)BCL2L14
DoCM (Curated mutations)BCL2L14
CIViC (Clinical Interpretations of Variants in Cancer)BCL2L14
Impact of mutations[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Genetic Testing Registry BCL2L14
NextProtQ9BZR8 [Medical]
Target ValidationBCL2L14
Huge Navigator BCL2L14 [HugePedia]
Clinical trials, drugs, therapy
Protein Interactions : CTDBCL2L14
Pharm GKB GenePA134870762
Clinical trialBCL2L14
DataMed IndexBCL2L14
PubMed35 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Thu Jan 20 14:02:44 CET 2022

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us